Physician profile
Gary J Maszak
NPI 1962443812
$1,329.93
in general payments reported to CMS, 2019-2025
15 companies · $287 in 2025
The $287 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53.46 · 2020: $25.69 · 2021: $47.85 · 2022: $501 · 2023: $205 · 2024: $210 · 2025: $287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $702.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $701.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $376.74 | 2022-2025 | Avvigo Guidance System, Opticross, Wolverine Coronary Cutting Balloon |
| Acist Medical Systems, INC. | $302.76 | 2022-2025 | |
| Inari Medical, INC. | $149.15 | 2022 | |
| Abiomed | $107.25 | 2023-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $82.50 | 2019-2022 | |
| Abbott Laboratories | $49.41 | 2025 | Perclose Proglide |
| Amarin Pharma, INC. | $43.18 | 2021-2022 | |
| Cvrx, INC. | $42.14 | 2024 | Barostim Neo System |
| Cardiva Medical, INC. | $41.17 | 2022-2025 | Cardiva Vascade 6/7f Vcs |
| Cordis US Corp. | $36.56 | 2025 | Mynx Control Venous |
| Shockwave Medical, INC | $27.75 | 2021 | |
| Janssen Pharmaceuticals, INC | $20.60 | 2022 | |
| Biosense Webster, INC. | $19.50 | 2025 | Nuvision Ice Catheter |
| Amgen INC. | $15.68 | 2019 | |
| Chiesi USA, INC. | $15.54 | 2024 | Kengreal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Maszak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.